Bavarian Nordic A/S | Mutual Funds
Mutual Funds that own Bavarian Nordic A/S
ATP Group Portfolio
2,069,109
6.4%
-400,754
0.04%
12/31/2017
Oppenheimer Global Opportunities Fund
800,000
2.48%
0
0.25%
03/31/2018
Government Pension Fund - Global (The)
647,630
2%
-601,137
0%
12/31/2017
Vanguard Total International Stock Index Fund
450,508
1.39%
0
0%
07/31/2018
Gladiator
350,000
1.08%
350,000
1.89%
12/31/2016
Danske Invest Danmark Fokus
235,899
0.73%
-202
1.14%
08/31/2018
DFA Continental Small Company Series
204,295
0.63%
0
0.1%
01/31/2018
Vanguard Developed Markets Index Fund
183,668
0.56%
0
0.01%
07/31/2018
CREF Stock Account
159,922
0.5%
-20,766
0%
03/31/2018
Danske Invest Engros Flexinvest Aktier
154,725
0.48%
0
0.17%
08/31/2018
| Address |
Hejreskovvej 10A
Kvistgaard CR 3490
Denmark
|
|
Employees
|
- |
| Website |
http://www.bavarian-nordic.com |
| Updated |
07/08/2019 |
| Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. |
